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Background: Adjuvant Online (AOL) is web-accessible risk-assessment model that predicts the mortality and the
benefits of adjuvant therapy (www.newadjuvantonline.com). AOL has never been validated for Asian colon cancer
patients.
Methods: Using the Yonsei Tumor Registry database, patients who were treated within the Yonsei University
Health System between 1990 and 2005 for T1-4, N0-2, and M0 colon cancer were included in the calculations for
survival. Observed and predicted 5-year overall survival was compared for each patient.
Results: The median age of the study population of 1431 patients was 60 years (range, 15–87 years), and the
median follow-up duration was 7.9 years (range, 0.06–19.8 years). The predicted 5-year overall survival rate (77.7%)
and observed survival (79.5%) was not statistically different (95% Confidential interval, 76.3–81.5) in all patients.
Predicted outcomes were within 95% confidential interval of observed survival in both stage II and III disease,
including most demographic and pathologic subgroups. Moreover, AOL more accurately predicted OS for patients
with stage II than stage III.
Conclusions: AOL tended to offer reliable prediction for 5-year overall survival and could be used as a decision
making tool for adjuvant treatment in Korean colon cancer patients whose prognosis is similar to other Asian
patients.
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Colon cancer is the third most common cancer in Western
countries, and its incidence is rapidly increasing in Asia
[1]. The main prognostic factor for survival after surgery
for localized disease is tumor stage [2]. Approximately 40%
of colon cancer patients have lymph node involvement and
20% have node negative, T3, or T4 disease [3]. Adjuvant
chemotherapy after surgery for stage III colon cancer has
become a standard therapy and is credited for an estimated
33% reduction in the risk of colon cancer recurrence [4,5].
However, the prognosis of survival for stage II colon cancer* Correspondence: SSJ338@yuhs.ac
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reproduction in any medium, provided the oris different from that of stage III, and the benefit of ad-
juvant therapy for stage II remains unclear [2]. There-
fore, recommendations for adjuvant treatment in colon
cancer patients are based on the clinician’s estimated
risk assessment for colon cancer relapse or death and
the likely benefit of the therapy.
However, predicting the absolute benefit of adjuvant sys-
temic therapy for an individual patient with colon cancer is
complex. To solve this problem, two decision support tools
have been developed [6,7]. Adjuvant! Online (AOL, www.
newadjuvantonline.com) is a computerized, web-accessible,
risk assessment model that predicts mortality, recurrence
risk, and benefit of adjuvant therapy for Western patients
with colon cancer. The program provides estimates for
5-year overall survival (OS), colon cancer-specific survival
(CCSS), and disease-free survival (DFS) based on thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nodal status, and adjuvant chemotherapy. AOL was devel-
oped based on information from the Surveillance, Epi-
demiology and End Results (SEER) registry [6].
Recently, this model has been externally validated in
Western patients with colon cancer and acceptable predic-
tion for survival of patients with stage III was observed
[8]. However, this model has never been validated in Asian
colon cancer patients, whose characteristics are different
from Western patients. Some studies have reported ethnic
differences in tumor stage and survival. Among non-
Hispanic Whites, non-Hispanic Blacks, Hispanics, and
Asian/Pacific Islanders, Blacks were more likely than
Whites to have advanced stage disease and Asians/PacificTable 1 Baseline characteristics and 5-year survival predicted
Number % AOL pred
All patients 666 100 77.07
Age
< 50 107 16.1 83.31
50-59 148 22.2 80.61
60-69 227 34.1 78.34
≥ 70 184 27.6 69.03
Sex
Male 400 60.1 76.19
Female 266 39.4 78.40
T stage
T1 79 11.9 91.08
T2 117 17.5 85.76
T3 456 68.5 72.83
T4 14 2.1 63.57
Number of positive nodes
0 501 75.2 83.92
1-3 111 16.7 62.65
4-10 47 7.1 46.79
> 10 7 1.0 19.00
Number of examined nodes
1-3 27 4.1 85.56
4-10 122 18.3 78.75
> 10 517 77.6 76.23
Histologic grade
1 110 16.5 81.67
2 455 68.3 75.77
3 32 4.8 72.59
Undefined 69 10.4 80.38
*This predicted estimate is outside the 95% CI of the Kaplan-Meier estimate.
AOL: Adjuvant Online; YTR: Yonsei Tumor registry; CI: confidential interval; Pred: predIslanders had a lower risk of death from colorectal cancer
in the same stage [9-12].
Therefore, the aim of this study was to evaluate whether
Western based prognostic model, AOL, could be a useful
tool in Korean colon cancer patients whose prognosis is
similar to other Asian patients.
Methods
Patients
Patients who were treated at the Yonsei University
Health System (YUHS) between 1990 and 2005 and
were identified in the Yonsei Tumor Registry (YTR)
database were included in the study if they met the fol-
lowing criteria: complete resection of colon cancer, withand observed in the patients with surgery alone
Mean % of 5-year survival % Delta
(Pred-Obs)icted YTR observed (95% CI)
79.73 (76.47, 82.59) −2.66
* 91.59 (84.46, 95.53) −8.28
83.78 (76.79, 88.82) −3.17
80.17 (74.37, 84.8) −1.83
69.01 (61.78, 75.15) 0.02
78.75 (74.41, 82.44) −2.56
81.2 (75.97, 85.41) −2.8
94.94 (87.07, 98.07) −3.86
83.76 (75.73, 89.32) 2
76.97 (72.82, 80.57) −4.14
50 (22.86, 72.21) 13.57
84.83 (81.38, 87.69) −0.91
67.56 (57.99, 75.4) −4.91
59.57 (44.21, 71.99) −12.78
42.86 (9.78, 73.44) −23.86
88.89 (69.39, 96.27) −3.33
72.13 (63.26, 79.21) 6.62
* 81.04 (77.39, 84.17) −4.81
82.73 (74.27, 88.62) −1.06
78.9 (74.85, 82.37) −3.13
81.25 (62.95, 91.11) −8.66
79.71 (68.16, 87.45) 0.67
icted; Obs: observed.
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on surgical exploration, and all lesions located between
the cecum and the rectosigmoid. Based on AOL criteria,
clinicopathological variables collected in this study
included age, sex, T stage, number of examined lymph
nodes, number of positive lymph nodes, histologic grade,
and treatment with adjuvant chemotherapy. Patients
with previous malignant disease; those who received
neoadjuvant therapy; or those who they had unknown
tumor size, nodal status, or adjuvant systemic therapy sta-
tus were excluded. The study was approved by the YUHS
institutional review board (IRB number: 4-2010-0178).Treatment protocol
Adjuvant chemotherapy was administered to patients with
adjuvant chemotherapy was administered to patients with
node positive or T3-4 tumors. Adjuvant chemotherapy
was a 5-fluourouracil (5-FU) based regimen that was
administered for 6 months.Data analysis
The aim of this study was comparisons between the pre-
dicted and observed OS. The observed OS was mea-
sured from the date of diagnosis to the date of death.
The observed outcome for each patient was obtained
from the YTR database and Korea National Statistical
Office (KNSO). Using the same patient population, the
predicted 5-year OS values were derived for each patient
using the standard AOL version available in October
2010. The input options for AOL were age, sex, comor-
bidity, depth of invasion, positive nodes, examined
nodes, histologic grade, and adjuvant systemic therapy.
The default comorbidity assumption of “minor health
problems” was used, since we could not retrieve reliable
comorbidity data from YTR.Figure 1 Comparison of AOL predicted and observed 5-year
survival in patients with underwent surgery alone.Statistical analysis
The observed 5-year OS was compared using the method
of Kaplan-Meier (KM) with predicted estimate from AOL.
For the same datasets, the average predicted OS was cal-
culated from individual predicted outcomes by AOL. The
observed and predicted survivals were compared by de-
scriptive manner using the absolute difference. If predicted
values were within 95% confidential interval of observed
OS, we considered AOL to accurately predict OS. The
AOL predictions were divided into 5% intervals, and inter-
vals were grouped so that each interval contained at least
50 patients. The observed KM estimations for each inter-
val subset were plotted against the average prediction for
AOL. All analyses were performed using SAS version 9.2
(SAS Inc., Cary, NC) and R statistical software.Results
Patient characteristics
Among 1598 patients with T1-4, N0-2, M0 colon cancer
diagnosed at YUHS, 1431 (89.5%) met our eligibility cri-
teria. For this study, we excluded synchronous colon can-
cer (n = 20), unknown T stage or nodal status (n = 21), or
less than 5 years of follow-up duration (n = 126). The me-
dian age was 60 years (range, 15–87 years). Among all
study patients, 81.6% had T3 stage and 64% had no lymph
node metastasis. More than 10 lymph nodes were har-
vested in 84% patients. Of all, 765 patients (53.4%) under-
went surgery and received adjuvant 5-FU chemotherapy.
The 420 (45.6%) of 921 patients treated with chemother-
apy were node negative and T3 or T4 tumor. And 165
(32.5%) of 510 patients who had lymph node-positive did
not receive chemotherapy. Among 165 patients, 43
patients did not receive chemotherapy due to old age, 37
patients due to poor performance status, 61 patients due
to postoperative complication and 24 patients refused
chemotherapy. Over the median follow-up duration of 7.9
years (range, 0.06–19.8 years), 448 of 1431 patients
(31.3%) died before October 31, 2010. Among them, 292
patients (65.2%) died due to colon cancer and 123 (27.5%)
died unrelated to cancer. There were 33 cases (7.4%) of
metachronous second primary cancer related deaths.
Application of AOL to Korean patients with surgery alone
For all patients (n = 1431), the predicted 5-year overall
survival rate (77.7%) and observed survival (79.3%) was
not statistically different (95% Confidential interval [CI],
77.3–81.5). Table 1 shows comparisons between AOL pre-
dictions and observations for 5-year KM rate with 95% CI
based on demographic and pathologic parameters in
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dicted survival differed from the median observed 5-year
survival rate by 2.7%; however, predicted survival rate
was within 95% CI of the KM estimate. For lymph node-
negative, stage II subgroup (75.2%), AOL exactly estimated
OS with difference rate by 0.9%. In addition, AOL estimates
were within the observed 95% CI for OS in all subgroups
(20 of 21 subgroups), except two subgroups. AOL underes-
timated OS in patients younger than age of 50 (predicted-
observed = −8.3%), and these predictions were outside the
95% CI of KM estimate, and patients with more than 10
lymph nodes examined. Figure 1 shows the relationship
between predicted and observed OS divided into 5%
intervals in patients with surgery alone.Table 2 Baseline characteristics and 5-year survival predicted
chemotherapy
Number % AOL pr
All patients 765 100 78
Age
< 50 177 23.1 83
50-59 226 29.5 79
60-69 270 35.3 76
≥ 70 92 12.1 69
Sex
Male 450 58.8 77
Female 315 41.2 79
T stage
T1 4 0.5 89
T2 20 2.6 82
T3 712 93.1 78
T4 29 3.8 59
Number of positive node
0 420 54.9 86
1-3 242 31.6 74
4-10 79 10.3 57
> 10 24 3.2 34
Number of examined nodes
1-3 3 0.4 79
4-10 83 10.9 76
> 10 679 88.7 78
Histologic grade
1 94 12.3 82
2 561 73.3 78
3 44 5.8 69
Undefined 66 8.6 75
*This predicted estimate is outside the 95% CI of the Kaplan-Meier estimate.
AOL: Adjuvant Online; YTR: Yonsei Tumor registry; CI: confidential interval; Pred: predApplication of AOL to Korean patients underwent surgery
plus 5-FU chemotherapy
In Table 2 presents the overall and subgroup univariate
mean predictions for AOL and the observed OS in
patients who underwent surgery and received 5-FU based
chemotherapy. The difference between estimates and
observed 5-year OS rate in all patients (n = 765) was 1.2%.
Except three subgroups which had small number of
patients, predicted OS in all subgroup were in 95% CI of
the observed OS by KM estimate. For patients with stage
II (n = 420), AOL demonstrated excellent prediction ac-
curacy for OS, differing by 0.4%. Figure 2 illustrated AOL
average predicted estimates for 5-year OS compared with
the observed KM estimates.and observed in the patients with surgery plus
Mean % of 5-Year outcomes % Delta
(Pred-Obs)edicted YTR observed (95% CI)
.19 79.35 (76.3, 82.05) −1.16
.37 87.57 (81.74, 91.63) −4.2
.56 80.09 (74.26, 84.73) −0.53
.51 76.3 (70.76, 80.93) 0.21
.75 70.65 (60.2, 78.84) −0.9
.57 78.67 (74.59, 82.17) −1.1
.06 80.32 (75.48, 84.3) −1.26
.50 75 (12.79, 96.05) 14.5
.35 85 (60.38, 94.9) −2.65
.78 80.48 (77.37, 83.2) −1.7
.21 48.28 (29.47, 64.78) 10.93
.87 86.43 (82.77, 89.36) 0.44
.31 77.27 (71.46, 82.05) −2.96
.24* 69.62 (58.19, 78.49) −12.38
.25* 8.33 (1.44, 23.3) 25.92
.33* 100 (100, 100) −20.67
.77 77.11 (66.49, 84.74) −0.34
.35 79.53 (76.29, 82.37) −1.18
.44 81.91 (72.53, 88.35) 0.53
.52 79.14 (75.54, 82.28) −0.62
.50 72.73 (57, 83.49) −3.23
.09 81.82 (70.21, 89.24) −6.73
icted; Obs: observed.
Figure 2 Comparison of AOL predicted and observed 5-year
survival in patients treated with surgery and chemotherapy.
Jung et al. BMC Cancer 2012, 12:471 Page 5 of 6
http://www.biomedcentral.com/1471-2407/12/471Discussion and conclusions
In Western population and clinical trial based validation,
AOL had reliable prediction of OS for colon cancer
patients [8]. This study was performed to test whether
AOL prediction of survival is applicable for the Korean
colon cancer patients, whose prognosis is similar to
other Asian patients [9,13,14].
In the current study, AOL had acceptable prediction
for OS for all patients and almost every subgroup. Espe-
cially, AOL more accurately predicted OS for patients
with stage II than stage III. Gil et al. [8] reported that
AOL had acceptable reliability for patients with stage III
disease and tended to overestimate survival for patients
with stage II disease who received 5-FU from the
population-based data.
What are the reasons for inverse validation between
Western and Korean population? One possible explan-
ation is ethnic difference. Asian colon cancer patients
tend to experience better survival than Western patients
in the same stage [9,11,12,15]. Our data showed that the
observed OS was better than that predicted by AOL, al-
though there was no statistical difference. Especially,
AOL overestimated survival by 8.3% in patients younger
than 50 years. Therefore, AOL tended to overestimate
survival for Western patients with stage II disease trea-
ted with 5-FU and exactly predicted survival for Korean
cancer patients with stage II.
The other possible reason of different validation is dif-
ferent subgroup between two populations. The median
age of Korean population was 8-year younger than the
Western population. Interestingly, the median age of the
clinical trial cohort of Western patients was 64 years
old, which is younger than population cohort of Western
patients. In both Gil et al. and current study, the default
comorbidity assumption of “minor health problems” wasused, since we could not retrieve reliable comorbidity
data from each cohort. Accordingly, Western population
cohort included more old age patients and high risk
comorbidity patients than the trial based cohort. AOL
overestimated survival in the western population cohort
and similarly estimated in the clinical trial cohort. In
contrast to this, Korean population cohort included
more young age and low risk comorbidity patients than
the Western population, which AOL accurately pre-
dicted survival for patients in stage II and III.
The last possible reason for the difference in predicted
and observed outcomes can also be explained by the
limitation of the AOL estimation regarding risk reduc-
tion by chemotherapy. Estimates of prognosis are mainly
based on the SEER estimates of outcome for colon can-
cer patients in the general population. The efficacy of
therapy is estimated based on the proportional risk
reductions that which were obtained from meta-analyses
of the effectiveness of adjuvant therapy and from the
data published or presented from individual randomized
clinical trials [6]. Therefore, AOL tended to overestimate
survival of Western colon cancer patients, and more ac-
curately predicted in Korean patients whose survival are
better than the Western patients.
Many studies have reported the number of evaluated
lymph nodes (ELN) was positively associated with sur-
vival of colon cancer patients with not only stage II, but
stage III [16]. However, some studies reported that the
number of ELN was positively correlated with survival
in stage II, but did not affect the long-term outcome in
stage III [13,17]. In the current study, no significant as-
sociation observed between ELN and survival. Kaplan-
Meier analyses demonstrated 5-year overall survival
rates for the number of ELN 1–3, 4–10, and > 10
of 90%, 73%, and 80%, respectively (Additional file 1:
Table S1). A possible reason why the patients with less
than 4 of ELN had the most favorable survival might be
that these patients had favorable variables than the other
patients, such as higher portion of younger age, low T
stage, less number of positive node, and lower histologic
grade (Additional file 2: Figure S1). In addition, the
number of patients with less than 4 of ELN was only 30
(2.1%). Except for these patients, the number of ELN
had positive trend of good survival in our study.
This study had several limitations. First, tumor grade
was not available for some of our cases (9.4%), and the
information of comorbidity could not be checked be-
cause the YTR is a retrospective database. Second, our
study examined a time period when the standard
chemotherapy was a 5-FU-based chemotherapy, the cur-
rently used oxaliplatin-based chemotherapy in patients
with stage III and high risk stage II, although predicted
survival used by AOL recommendation for the benefit of
5-FU based chemotherapy. Third, we had insufficient
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cinoembryonic antigen level [18], lymphovascular in-
volvement [19], microsatellite instability [20], and other
molecular markers [21].
In conclusion, we found that the AOL prediction sys-
tem, which is based on Western patients, is suitable for
Korean colon cancer patients with not only stage II but
also stage III. Therefore, AOL which is a easily accessed
tool, provides important information for the physician in
terms of survival for Korean and Asian colon cancer
patients, whose disease patterns and survival are similar
[9,13,14].
Additional files
Additional file 1: Table S1. Baseline characteristics according to
number of examined nodes (n=1431).
Additional file 2: Figure S1. Observed overall survival according to
number of examined nodes by Kaplan-Meier curve.
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